Conference Coverage

Empagliflozin favorably reshaped left ventricles in HFrEF patients

Publish date: November 15, 2020

 

FROM AHA 2020

mzoler@mdedge.com

Pages

Recommended Reading

Experts tout immediate quadruple therapy for HFrEF patients
MDedge Internal Medicine
When should students resume sports after a COVID-19 diagnosis?
MDedge Internal Medicine
Novel drug slows progression of diabetic kidney disease
MDedge Internal Medicine
Updated heart failure measures add newer meds
MDedge Internal Medicine
MADIT-CRT: Resynchronization linked to fewer heart failure hospitalizations
MDedge Internal Medicine
New return-to-play recommendations for athletes with COVID-19
MDedge Internal Medicine
No link shown between thyroid dysfunction and heart failure
MDedge Internal Medicine
GALACTIC-HF: New ‘myotropic’ drug class shows modest HFrEF benefit
MDedge Internal Medicine
TIPS-3: Polypill provides meaningful primary cardiovascular prevention
MDedge Internal Medicine
Intravenous iron reduces HF readmissions: AFFIRM-AHF
MDedge Internal Medicine